Results 131 to 140 of about 334,030 (336)

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source

The Effects of Complementary Therapies on Patient-Reported Outcomes: An Overview of Recent Systematic Reviews in Oncology. [PDF]

Cancers (Basel), 2023
Mentink M, Verbeek D, Noordman J, Timmer-Bonte A, von Rosenstiel I, van Dulmen S.   +5 more
europepmc   +1 more source

Biological Complementary Therapies: A Focus on Botanical Products in Diabetes [PDF]

, 2001
Laura Shane‐McWhorter
openalex   +1 more source

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

Molecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop, Edgar Cardenas De La Hoz, Hanne Verswyvel, Joey De Backer, Ho Wa Lau, Angela Privat‐Maldonado, Wim Vanden Berghe, Steve Vanlanduit, Evelien Smits, Annemie Bogaerts, Abraham Lin   +10 more
wiley   +1 more source

Editorial: Complementary therapies for neurological disorders: from bench to clinical practices. [PDF]

Front Neurol, 2023
Ye Y, Li S, Xiao L, Chang J.
europepmc   +1 more source

Use of complementary therapies by registered psychologists:An international study [PDF]

, 2015
Boucher, Emma, Chatwin, Hannah, Crebbin, Sue, Purkis, Gail, Scott, Sandra, Smith, Dean, Stapleton, Peta   +6 more
core   +1 more source

Hippotherapy and Therapeutic Riding: Practicing Social Workers and Undergraduate Social Work Students [PDF]

, 2010
This study attempted to explore, through the use of surveys, what practicing social workers and undergraduate student social workers know about hippotherapy and therapuetic riding.
Smith, Devin
core   +1 more source

Clinical training in complementary therapies for the 21st century [PDF]

Over the past six years an innovative portfolio of degree courses in complementary therapies has been developed at the University of Westminster.
Isbell, B., Isbell, B.
core   +1 more source

A Step-by-Step Approach to Complementary Therapies [PDF]

, 2001

openalex   +1 more source

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source